Memory's CEO steps down

Memory Pharmaceuticals' CEO Jim Sulat has announced plans to step down from the position for personal reasons. He will remain the company's part-time CFO. Taking his place for the time being is Vaughn Kailia, who has been appointed interim president and CEO. Kailia is an investor in Memory and a director at the company.

"I will work closely with the management team to review our programs and organizational structure to ensure that they are closely aligned with our goals and that we are well-positioned to achieve our vision for this company. We expect this review to be completed shortly," said Kailia in a statement.

- check out this release for more

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.